## GENERAL ASSEMBLY OF NORTH CAROLINA **SESSION 2015**

 $\mathbf{S}$ 

## **SENATE BILL 235 Health Care Committee Substitute Adopted 4/21/15**

Short Title:	Establish Advisory Council on Rare Diseases. (Public)				
Sponsors:					
Referred to:					
	March 11, 2015				
THE DEPA The General A	A BILL TO BE ENTITLED  TABLISHING AN ADVISORY COUNCIL ON RARE DISEASES WITHIN ARTMENT OF HEALTH AND HUMAN SERVICES.  Assembly of North Carolina enacts:				
adding a new l	<b>CTION 1.</b> Article 1B of Chapter 130A of the General Statutes is amended by				
adding a new i	"Part 5. Advisory Council on Rare Diseases."				
"§ 130A-33.52	2. Advisory Council on Rare Diseases; membership.				
(a) The	ere is established the Advisory Council on Rare Diseases within the Department				
	Secretary on research, diagnosis, treatment, and education relating to rare				
	purposes of this section, "rare disease" has the same meaning as provided in 21				
	b, as amended from time to time.				
	e advisory council shall consist of the following members, who shall be				
appointed by t					
<u>(1)</u>					
(2)	researching, diagnosing, or treating rare diseases.				
<u>(2)</u>	A medical researcher with experience conducting research concerning rare				
(3)	diseases.  A registered nurse or advanced practice registered nurse licensed and				
<u>(3)</u>	practicing in the State with experience treating rare diseases.				
<u>(4)</u>	<u>*                                      </u>				
<u> </u>	to persons diagnosed with a rare disease, or a designee of the hospital				
	administrator.				
<u>(5)</u>					
<u>(6)</u>	A caregiver of a pediatric rare disease survivor.				
<u>(7)</u>					
(8)	•				
<u>(9)</u>	<del> </del>				
<u>(10</u>	<u> </u>				
<u></u>	the State.				
<u>(c)</u> <u>The</u>	e chairpersons of the Joint Legislative Oversight Committee on Health and				
Human Services, or the chairpersons' designees, shall be members of the advisory council.					

- The Secretary, or the Secretary's designee, shall be an ex officio, nonvoting member (d) of the advisory council and shall attend all meetings of the advisory council.
- Any member of the advisory council appointed under subsection (c) of this section may be a member of the General Assembly.



- (f) All appointments to the advisory council shall be made not later than 30 days after the effective date of this section. Members appointed pursuant to subsection (b) of this section shall serve for a term of three years, and no member shall serve more than two consecutive terms.
- (g) Members of the advisory council shall receive per diem and necessary travel and subsistence expenses in accordance with the provisions of G.S. 138-5 or G.S. 138-6, or travel and subsistence expenses in accordance with the provisions of G.S. 120-3.1, as applicable.
- (h) All administrative support and other services required by the advisory council shall be provided by the Department.
- (i) The Secretary shall schedule the first meeting of the advisory council, which shall be held not later than October 1, 2015. The members shall elect the chairperson of the advisory council from among the members of the council. A majority of the council members shall constitute a quorum. A majority vote of a quorum shall be required for any official action of the advisory council. The advisory council shall meet upon the call of the chairperson or upon the request of a majority of council members.

## "§ 130A-33.53. Advisory Council on Rare Diseases; powers and duties.

The advisory council shall exercise the following powers and duties:

- (1) Coordinate statewide efforts for the study of the incidence of rare disease within the State and the status of the rare disease community.
- (2) Act as the advisory body on rare diseases to the Secretary on research, diagnosis, treatment, and education relating to rare diseases.
- (3) Coordinate the performance of the advisory council's duties with other rare disease advisory bodies, community-based organizations, and other public and private organizations within the State for the purpose of ensuring greater cooperation regarding the research, diagnosis, and treatment of rare diseases between the State and federal agencies, including but not exclusive to, the United States National Institutes of Health (NIH) and the United States Food and Drug Administration (FDA). Such coordination shall require, when appropriate, the following:
  - a. <u>Disseminating the advisory council's research, identified best practices, and policy recommendations.</u>
  - b. <u>Utilizing common research collection and dissemination procedures.</u>
- (4) Research and identify priorities relating to the quality and cost-effectiveness of, and access to, treatment and services provided to persons with rare diseases in the State; and develop policy recommendations on those issues.
- (5) Identify best practices for rare disease care from other states and at the national level that will improve rare disease care in this State.
- (6) Develop recommendations for effective strategies to raise public awareness of rare diseases in the State.
- (7) Determine recommendations for best practices for ensuring that the public and health care providers are sufficiently informed of the most effective strategies for recognizing and treating rare diseases.
- (8) Develop recommendations for effective strategies to aid in determining any genetic or environmental contributors to rare diseases.
- (9) Not later than January 1, 2016, and annually thereafter, the advisory council shall report to the Joint Legislative Oversight Committee on Health and Human Services on the activities of the advisory council and its findings and recommendations regarding rare disease research and care in North Carolina.
- (10) Apply for, and accept, any grant of money from the federal government, private foundations, or other sources which may be available for the

Page 2 S235 [Edition 2]

General Assembly Of North Carolina					Session 2015		
operation of the advisory of	council an	nd State	programs	related	to	rare	
diseases."							
<b>SECTION 2.</b> This act becomes effect	ctive July 1	1, 2015.					

S235 [Edition 2] Page 3